Table 4 Skin expression of Ki67 and pERK at cycle 1 day 15

From: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Median (range) percent of baseline

30 mg BID ( n =4)

45 mg BID ( n =22)

60 mg BID ( n =7)

Total ( N =33)

Ki67

44 (25–56)

33 (6–300)

31 (17–100)

33 (6–300)

pERK

88 (50–100)

66 (38–189)

59 (29–72)

64 (29–189)

  1. Abbreviations: BID=twice daily.
Back to article page